Screener / SEC EDGAR /CIK 0001088856 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Corcept Therapeutics Inc CORT

Compare with peers Embed
Planned sales, announced before they happen

9 trading plans running, 32 Form 144 notices for $103.7M

10-Q, 10-K and Form 144
Plans running now 9 William Guyer, Atabak Mokari, Daniel N. Swisher, Jr., Joseph K. Belanoff, M.D., Joseph D. Lyon, David L. Mahoney, James N. Wilson, Sean Maduck
Plans adopted 18 reported since May 3, 2023 Form 144 notices 32 $103.7M the sellers expected to sell

What CORT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Nov 27, 2024 to May 31, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
William Guyer
Chief Development Officer
Adopted 10b5-1 plan Aug 20, 2026 10-Q Nov 3, 2026
Atabak Mokari
Chief Financial Officer
Adopted 10b5-1 plan Aug 13, 2026 10-Q Nov 3, 2026
Daniel N. Swisher, Jr.
Director
Adopted 10b5-1 plan Aug 3, 2026 10-Q Nov 3, 2026
Joseph K. Belanoff, M.D.
Chief Executive Officer and Director
Adopted 10b5-1 plan Jun 11, 2026 10-Q Jul 29, 2026
Joseph D. Lyon
Chief Accounting & Technology Officer
Adopted 10b5-1 plan Jun 10, 2026 10-Q Jul 29, 2026
David L. Mahoney
Director
Adopted 10b5-1 plan May 19, 2026 10-Q Jul 29, 2026
James N. Wilson
Director
Adopted 10b5-1 plan Mar 12, 2026 10-Q Apr 30, 2026
Atabak Mokari
Chief Financial Officer
Adopted 10b5-1 plan Dec 12, 2025 10-K Feb 24, 2026
Sean Maduck
President, Corcept Endocrinology
Adopted 10b5-1 plan Dec 8, 2025 10-K Feb 24, 2026
William Guyer
Chief Development Officer
Adopted 10b5-1 plan Nov 27, 2024 10-K Feb 26, 2025
Joseph K. Belanoff, M.D.
Chief Executive Officer
Adopted 10b5-1 plan Nov 26, 2024 10-K Feb 26, 2025
Sean Maduck
President, Endocrinology
Adopted 10b5-1 plan Sep 5, 2024 10-Q Oct 30, 2024
Joseph D. Lyon
Chief Accounting and Technology Officer
Adopted 10b5-1 plan Aug 30, 2024 10-Q Oct 30, 2024
Daniel Swisher
Director
Adopted 10b5-1 plan Aug 1, 2024 10-Q Oct 30, 2024
William Guyer
Chief Development Officer
Adopted 10b5-1 plan Sep 14, 2023 10-Q Nov 1, 2023
Sean Maduck
President, Corcept Endocrinology
Adopted 10b5-1 plan Jun 20, 2023 10-Q Aug 2, 2023
Dan Swisher
Board of Director
Adopted 10b5-1 plan May 8, 2023 10-Q Aug 2, 2023
J.D. Lyon
Chief Accounting Officer
Adopted 10b5-1 plan May 8, 2023 10-Q Aug 2, 2023
Show the other 10 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 3, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 10, 2026 DANIEL SWISHER JR.
Director
1,500 $113K
Oct 1, 2026 Lyon Joseph Douglas
Officer
10,000 $1.2M
Sep 15, 2026 WILSON JAMES N
Director
30,000 $3.3M
Sep 14, 2026 Lyon Joseph Douglas
Officer
10,000 $1.1M
Sep 2, 2026 Vieira Roberto Wandenkolk
Officer
75,295 $8.3M
Aug 26, 2026 KIMBERLY PARK
Director
26,685 $3.3M
Aug 25, 2026 Maduck Sean
Officer
175,000 $22.0M
Aug 18, 2026 MAHONEY DAVID L
Director
103,606 $12.2M
Aug 17, 2026 Robb Gary Charles
Officer
10,000 $1.2M
Aug 4, 2026 Guyer William
Officer
20,000 $2.3M
Aug 3, 2026 Lyon Joseph Douglas
Officer
1,540 $176K
Jul 30, 2026 Mokari Atabak
Officer
40,000 $4.6M
Jul 7, 2026 Guyer William
Officer
20,000 $1.9M
Jun 16, 2026 MAHONEY DAVID L
Director
20,000 $1.7M
Jun 16, 2026 WILSON JAMES N
Director
30,000 $2.5M
Jun 2, 2026 Guyer William
Officer
20,000 $1.4M
Jun 1, 2026 BELANOFF JOSEPH K
Officer
12,837 $892K
Jun 1, 2026 Mokari Atabak
Officer
160,000 $11.2M
May 27, 2026 Maduck Sean
Officer
150,000 $9.8M
May 20, 2026 Lyon Joseph Douglas
Officer
5,000 $291K
May 5, 2026 Guyer William
Officer
20,000 $1.0M
May 1, 2026 BELANOFF JOSEPH K
Officer
40,000 $1.9M
Apr 7, 2026 Guyer William
Officer
20,000 $817K
Mar 25, 2026 BELANOFF JOSEPH K
Officer
40,000 $1.4M
Mar 4, 2026 Guyer William
Officer
20,000 $706K
Feb 3, 2026 Guyer William
Officer
20,000 $814K
Jan 6, 2026 Guyer William
Officer
20,000 $699K
Dec 2, 2025 Guyer William
Officer
20,000 $1.6M
Dec 1, 2025 BELANOFF JOSEPH K
Officer
40,000 $3.2M
Dec 1, 2025 Maduck Sean
Officer
20,000 $1.6M
Dec 1, 2025 Lyon Joseph Douglas
Officer
5,000 $397K
Nov 25, 2025 Guyer William
Officer
4,500 $364K
Show the other 24 notices

From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.